AMPH

Across TCGA pan-cancer cohorts, AMPH mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated AMPH data layer compared with 24 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher AMPH mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AMPH expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LUAD, PDAC, and UCEC are the cancer types where AMPH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	All	0.866	0.971	.015	26	view →
PDAC	DFS	Tertile	All	0.459	0.276	.006	18	view →
UCEC	OS	Quartile	II,III,IV	0.541	1.000	.042	12	view →
CCRCC	OS	Tertile	IV	0.830	0.198	.024	6	view →
HNSC	DFS	Quartile	All	0.608	0.835	.027	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

AMPH–LUAD (DFS)

Open the LUAD breakdown →